Trial · NCT01515345

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

NCT01515345, Phase 3, Completed, Kaiser Franz Josef Hospital; results first posted 2013-05-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry. Trials, record NCT01515345. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01515345

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
NCT number: NCT01515345
Status: Completed
Phases: Phase 3
Enrollment: 1,008 participants, actual
Lead sponsor: Kaiser Franz Josef Hospital
Conditions: Platelet Inhibition, Coronary Stent Implantation
Interventions: prasugrel or ticagrelor, Clopidogrel
First posted: 2012-01-24
Last updated: 2017-04-25
Results first posted: 2013-05-01

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Definite Stent Thrombosis	30 days	The angiographic or pathological confirmation of stent thrombosis is called "definite stent thrombosis"
Primary	Any Bleeding Event	30days	Bleeding classified by the TIMI hemorrhage classification scheme: Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to \< 5 g/dL Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of \> 5 g/dL
Secondary	Probable Stent Thrombosis	30days	Probable stent thrombosis is considered to have occurred in case of 1. any unexplained death within the first 30 days. 2. any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Definite Stent Thrombosis	30 days	participants	NUMBER
PRIMARY	Any Bleeding Event	30days	participants	NUMBER
SECONDARY	Probable Stent Thrombosis	30days	participants	NUMBER

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Definite Stent Thrombosis	Standard Therapy	1	participants
Definite Stent Thrombosis	Individualized Therapy	0	participants
Any Bleeding Event	Standard Therapy	17	participants
Any Bleeding Event	Individualized Therapy	9	participants
Probable Stent Thrombosis	Standard Therapy	2	participants
Probable Stent Thrombosis	Individualized Therapy	0	participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Standard Therapy	665
Overall Study	STARTED	Individualized Therapy	343
Overall Study	COMPLETED	Standard Therapy	664
Overall Study	COMPLETED	Individualized Therapy	343
Overall Study	NOT COMPLETED	Standard Therapy	1
Overall Study	NOT COMPLETED	Individualized Therapy	0

Source ClinicalTrials.gov

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
serious	Definite stentthrombosis	Cardiac disorders	Standard Therapy	1	664	1
serious	Definite stentthrombosis	Cardiac disorders	Individualized Therapy	0	343	0
serious	probable Stentthrombosis	Cardiac disorders	Standard Therapy	2	664	2
serious	probable Stentthrombosis	Cardiac disorders	Individualized Therapy	0	343	0
serious	Cardiovascular death	Cardiac disorders	Standard Therapy	6	664	6
serious	Cardiovascular death	Cardiac disorders	Individualized Therapy	9	343	9
serious	Bleeding (TIMI major)	Cardiac disorders	Standard Therapy	6	664	6
serious	Bleeding (TIMI major)	Cardiac disorders	Individualized Therapy	4	343	4
serious	Bleeding (TIMI minor)	Cardiac disorders	Standard Therapy	11	664	11
serious	Bleeding (TIMI minor)	Cardiac disorders	Individualized Therapy	5	343	5

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Standard Therapy
Total, all-cause mortality	Individualized Therapy
Total, other adverse events	Standard Therapy	0	0
Total, other adverse events	Individualized Therapy	0	0
Total, serious adverse events	Standard Therapy	26	664
Total, serious adverse events	Individualized Therapy	18	343

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
18387444	BACKGROUND	PubMed
19264241	BACKGROUND	PubMed
21406646	BACKGROUND	PubMed
25361837	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Standard Therapy vs Individualized Therapy: Any Bleeding Event	Trial comparisons
Standard Therapy vs Individualized Therapy: Probable Stent Thrombosis	Trial comparisons
Standard Therapy vs Individualized Therapy: Definite Stent Thrombosis	Trial comparisons
Standard Therapy vs Individualized Therapy: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01515345

GET https://conductscience.org/api/trials/v1/NCT01515345/registered

API reference For AI assistants